Pluristem Therapeutics, Inc. (PSTI) Announces Earnings Results
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08), Zacks reports.
Pluristem Therapeutics (NASDAQ PSTI) opened at $1.46 on Tuesday. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $2.12.
ILLEGAL ACTIVITY WARNING: “Pluristem Therapeutics, Inc. (PSTI) Announces Earnings Results” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/pluristem-therapeutics-inc-psti-announces-earnings-results/1701955.html.
A number of equities research analysts have weighed in on PSTI shares. Seaport Global Securities restated a “buy” rating and set a $5.00 price objective on shares of Pluristem Therapeutics in a research note on Friday, October 6th. Maxim Group restated a “buy” rating and set a $2.00 price objective on shares of Pluristem Therapeutics in a research note on Tuesday, September 5th. HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 17th. ValuEngine upgraded Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Zacks Investment Research lowered Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $4.38.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.